• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥胖患者的评估和生活方式管理:系统评价的临床建议。

Assessment and lifestyle management of patients with obesity: clinical recommendations from systematic reviews.

机构信息

Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Pennington Biomedical Research Center, Baton Rouge, Louisiana.

出版信息

JAMA. 2014 Sep 3;312(9):943-52. doi: 10.1001/jama.2014.10432.

DOI:10.1001/jama.2014.10432
PMID:25182103
Abstract

IMPORTANCE

Even though one-third of US adults are obese, identification and treatment rates for obesity remain low. Clinician engagement is vital to provide guidance and assistance to patients who are overweight or obese to address the underlying cause of many chronic diseases.

OBJECTIVES

To describe current best practices for assessment and lifestyle management of obesity and to demonstrate how the updated Guidelines (2013) for Managing Overweight and Obesity in Adults based on a systematic evidence review sponsored by the National Heart, Lung, and Blood Institute (NHLBI) can be applied to an individual patient.

EVIDENCE REVIEW

Systematic evidence review conducted for the Guidelines (2013) for Managing Overweight and Obesity in Adults supports treatment recommendations in 5 areas (risk assessment, weight loss benefits, diets for weight loss, comprehensive lifestyle intervention approaches, and bariatric surgery); for areas outside this scope, recommendations are supported by other guidelines (for obesity, 1998 NHLBI-sponsored obesity guidelines and those from the National Center for Health and Clinical Excellence and Canadian and US professional societies such as the American Association of Clinical Endocrinologists and American Society of Bariatric Physicians; for physical activity recommendations, the 2008 Physical Activity Guidelines for Americans); a PubMed search identified recent systematic reviews covering depression and obesity, motivational interviewing for weight management, metabolic adaptation to weight loss, and obesity pharmacotherapy.

FINDINGS

The first step in obesity management is to screen all adults for overweight and obesity. A medical history should be obtained assessing for the multiple determinants of obesity, including dietary and physical activity patterns, psychosocial factors, weight-gaining medications, and familial traits. Emphasis on the complications of obesity to identify patients who will benefit the most from treatment is more useful than using body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) alone for treatment decisions. The Guidelines (2013) recommend that clinicians offer patients who would benefit from weight loss (either BMI of ≥30 with or without comorbidities or ≥25 along with 1 comorbidity or risk factor) intensive, multicomponent behavioral intervention. Some clinicians do this within their primary care practices; others refer patients for these services. Weight loss is achieved by creating a negative energy balance through modification of food and physical activity behaviors. The Guidelines (2013) endorse comprehensive lifestyle treatment by intensive intervention. Treatment can be implemented either in a clinician's office or by referral to a registered dietitian or commercial weight loss program. Weight loss of 5% to 10% is the usual goal. It is not necessary for patients to attain a BMI of less than 25 to achieve a health benefit.

CONCLUSIONS AND RELEVANCE

Screening and assessment of patients for obesity followed by initiation or referral of treatment should be incorporated into primary care practice settings. If clinicians can identify appropriate patients for weight loss efforts and provide informed advice and assistance on how to achieve and sustain modest weight loss, they will be addressing the underlying driver of many comorbidities and can have a major influence on patients' health status.

摘要

重要性

尽管美国有三分之一的成年人肥胖,但肥胖的识别和治疗率仍然很低。临床医生的参与对于为超重或肥胖患者提供指导和帮助至关重要,以解决许多慢性疾病的根本原因。

目的

描述肥胖评估和生活方式管理的当前最佳实践,并展示基于国家心肺血液研究所(NHLBI)赞助的系统证据审查的 2013 年《管理超重和肥胖成年人指南》(以下简称《指南》)如何应用于个体患者。

证据审查

为《指南》(2013 年)进行的系统证据审查支持 5 个领域(风险评估、减肥益处、减肥饮食、综合生活方式干预方法和减重手术)的治疗建议;对于超出此范围的领域,建议由其他指南支持(肥胖领域,1998 年 NHLBI 赞助的肥胖指南以及国家卫生与临床卓越中心和加拿大及美国专业协会的指南,如美国临床内分泌医师协会和美国减重医师协会;体力活动建议,2008 年《美国人体力活动指南》);PubMed 搜索确定了最近涵盖抑郁和肥胖、体重管理的动机性访谈、体重减轻的代谢适应以及肥胖药物治疗的系统评价。

发现

肥胖管理的第一步是筛查所有超重和肥胖的成年人。应获取病史,评估肥胖的多个决定因素,包括饮食和体力活动模式、社会心理因素、增重药物和家族特征。强调肥胖的并发症,以确定最能从治疗中受益的患者,比仅使用体重指数(BMI;体重以千克为单位除以身高以米为单位)来做出治疗决策更有用。《指南》(2013 年)建议临床医生为那些可能受益于减肥的患者提供强化、多组分的行为干预,无论是 BMI 为≥30 伴或不伴合并症,还是 BMI 为≥25 伴 1 种合并症或危险因素。一些临床医生在其初级保健实践中这样做;其他人则将患者转介给这些服务。通过改变食物和体力活动行为来创造负能量平衡从而实现减肥。《指南》(2013 年)支持通过强化干预进行综合生活方式治疗。治疗可以在医生办公室进行,也可以通过转介给注册营养师或商业减肥计划进行。通常目标是减轻 5%至 10%的体重。患者不必将 BMI 降低到 25 以下就能获得健康益处。

结论和相关性

应将肥胖患者的筛查和评估以及治疗的启动或转介纳入初级保健实践中。如果临床医生能够识别出适合减肥的患者,并就如何实现和维持适度减肥提供明智的建议和帮助,他们将解决许多合并症的根本原因,并对患者的健康状况产生重大影响。

相似文献

1
Assessment and lifestyle management of patients with obesity: clinical recommendations from systematic reviews.肥胖患者的评估和生活方式管理:系统评价的临床建议。
JAMA. 2014 Sep 3;312(9):943-52. doi: 10.1001/jama.2014.10432.
2
The effectiveness of web-based programs on the reduction of childhood obesity in school-aged children: A systematic review.基于网络的项目对学龄儿童肥胖症减轻的有效性:一项系统评价。
JBI Libr Syst Rev. 2012;10(42 Suppl):1-14. doi: 10.11124/jbisrir-2012-248.
3
4
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
5
The effect of weight management interventions that include a diet component on weight-related outcomes in pregnant and postpartum women: a systematic review protocol.包含饮食成分的体重管理干预措施对孕妇和产后女性体重相关结局的影响:一项系统评价方案
JBI Database System Rev Implement Rep. 2015 Jan;13(1):88-98. doi: 10.11124/jbisrir-2015-1812.
6
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.美国临床内分泌医师协会和美国内分泌学会肥胖患者医疗护理综合临床实践指南
Endocr Pract. 2016 Jul;22 Suppl 3:1-203. doi: 10.4158/EP161365.GL. Epub 2016 May 24.
7
Obesity Management in Adults: A Review.成人肥胖管理:综述。
JAMA. 2023 Nov 28;330(20):2000-2015. doi: 10.1001/jama.2023.19897.
8
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
9
Identification, evaluation, and management of obesity in an academic primary care center.学术性初级保健中心中肥胖症的识别、评估与管理。
Pediatrics. 2004 Aug;114(2):e154-9. doi: 10.1542/peds.114.2.e154.
10
Intermittent fasting interventions for the treatment of overweight and obesity in adults aged 18 years and over: a systematic review protocol.间歇性禁食干预治疗18岁及以上成年人超重和肥胖:一项系统评价方案
JBI Database System Rev Implement Rep. 2015 Oct;13(10):60-8. doi: 10.11124/jbisrir-2015-2363.

引用本文的文献

1
Healthcare professionals' perspectives on the current state of obesity management training: A mix methods study.医疗保健专业人员对肥胖管理培训现状的看法:一项混合方法研究。
Obes Pillars. 2025 Aug 19;16:100202. doi: 10.1016/j.obpill.2025.100202. eCollection 2025 Dec.
2
Comparative analysis of metabolic risks and related non-communicable disease burden across sociodemographic index regions from 1990 to 2021.1990年至2021年不同社会人口学指数地区代谢风险及相关非传染性疾病负担的比较分析
BMJ Open. 2025 Aug 10;15(8):e097748. doi: 10.1136/bmjopen-2024-097748.
3
Progress and challenges in obesity pharmacotherapy: semaglutide as a milestone.
肥胖药物治疗的进展与挑战:司美格鲁肽作为一个里程碑
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 14. doi: 10.1007/s00210-025-04319-0.
4
Differences between Type 2 Diabetes Mellitus and Obesity Management: Medical, Social, and Public Health Perspectives.2型糖尿病与肥胖管理的差异:医学、社会和公共卫生视角
Diabetes Metab J. 2025 Jul;49(4):565-579. doi: 10.4093/dmj.2025.0278. Epub 2025 Jun 11.
5
Anti-aging protein α-Klotho is potential for reducing comorbidity risk of cardiometabolic diseases in vulnerable populations and enhancing long-term prognosis.抗衰老蛋白α-klotho有可能降低脆弱人群中心血管代谢疾病的合并症风险,并改善长期预后。
Sci Rep. 2025 May 14;15(1):16722. doi: 10.1038/s41598-025-01580-4.
6
Obesity as a Disease: A Primer on Clinical and Physiological Insights.肥胖作为一种疾病:临床与生理见解入门
Methodist Debakey Cardiovasc J. 2025 Feb 18;21(2):4-13. doi: 10.14797/mdcvj.1515. eCollection 2025.
7
Lipids dysregulation in diseases: core concepts, targets and treatment strategies.疾病中的脂质失调:核心概念、靶点与治疗策略。
Lipids Health Dis. 2025 Feb 21;24(1):61. doi: 10.1186/s12944-024-02425-1.
8
Blood pressure, gallstones, and age at first cholecystectomy in U.S. adults: a cross-sectional study.美国成年人的血压、胆结石与首次胆囊切除术时的年龄:一项横断面研究。
BMC Gastroenterol. 2025 Feb 7;25(1):65. doi: 10.1186/s12876-025-03641-4.
9
Rheumatic Diseases Following Metabolic and Bariatric Surgery: A Systematic Review and Meta-Analysis.代谢与减重手术后的风湿性疾病:一项系统评价与荟萃分析
Obes Surg. 2025 Feb;35(2):624-634. doi: 10.1007/s11695-024-07652-0. Epub 2025 Jan 2.
10
Association between cardiometabolic index and all-cause and cause-specific mortality among the general population: NHANES 1999-2018.普通人群中心血管代谢指数与全因死亡率及特定病因死亡率之间的关联:1999 - 2018年美国国家健康与营养检查调查(NHANES)
Lipids Health Dis. 2024 Dec 27;23(1):425. doi: 10.1186/s12944-024-02408-2.